marketcaparena
Search

    AMGN

    AMGEN INC

    Company overview

    Market capitalization
    $226.05B
    Employees
    31,500
    Latest publication
    2026-09-29
    About AMGEN INC

    Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue10,054,000,000USD8,618,000,000USD9,896,000,000USD9,557,000,000USD9,167,000,000USD8,149,000,000USD9,086,000,000USD8,503,000,000USD
    Cost Of Revenue2,811,000,000USD2,744,000,000USD1,790,000,000USD3,082,000,000USD3,011,000,000USD2,968,000,000USD3,112,000,000USD3,310,000,000USD
    Gross Profit7,243,000,000USD5,874,000,000USD8,106,000,000USD6,475,000,000USD6,156,000,000USD5,181,000,000USD5,974,000,000USD5,193,000,000USD
    Research Development1,868,000,000USD1,719,000,000USD2,151,000,000USD1,900,000,000USD1,744,000,000USD1,486,000,000USD1,724,000,000USD1,450,000,000USD
    Selling General Administrative1,745,000,000USD1,602,000,000USD1,952,000,000USD1,720,000,000USD1,691,000,000USD1,687,000,000USD891,000,000USD1,625,000,000USD
    Selling And Marketing Expenses1,155,000,000USD—————987,000,000USD—
    General And Administrative Expenses590,000,000USD———————
    Other Operating Expenses116,000,000USD———————
    Total Operating Expenses3,729,000,000USD3,208,000,000USD4,164,000,000USD3,949,000,000USD3,512,000,000USD4,003,000,000USD3,663,000,000USD3,146,000,000USD
    Operating Income3,514,000,000USD2,666,000,000USD3,942,000,000USD2,526,000,000USD2,644,000,000USD1,178,000,000USD2,311,000,000USD2,047,000,000USD
    Total Other Income Expense Net-746,000,000USD-582,000,000USD-2,428,000,000USD1,395,000,000USD-1,076,000,000USD795,000,000USD-1,529,000,000USD1,054,000,000USD
    Interest Expense673,000,000USD657,000,000USD653,000,000USD685,000,000USD708,000,000USD723,000,000USD747,000,000USD776,000,000USD
    Income Before Tax2,768,000,000USD2,084,000,000USD1,514,000,000USD3,921,000,000USD1,568,000,000USD1,973,000,000USD782,000,000USD3,101,000,000USD
    Income Tax Expense393,000,000USD265,000,000USD181,000,000USD705,000,000USD136,000,000USD243,000,000USD155,000,000USD271,000,000USD
    Net Income2,375,000,000USD1,819,000,000USD1,333,000,000USD3,216,000,000USD1,432,000,000USD1,730,000,000USD627,000,000USD2,830,000,000USD
    Interest Income—101,000,000USD——————
    Unclassified Operating Expenses——61,000,000USD329,000,000USD77,000,000USD830,000,000USD61,000,000USD71,000,000USD
    Net Interest Income——-653,000,000USD-685,000,000USD-694,000,000USD-723,000,000USD-747,000,000USD-776,000,000USD
    Tax Provision——181,000,000USD705,000,000USD136,000,000USD243,000,000USD155,000,000USD271,000,000USD
    Net Income From Continuing Ops——1,333,000,000USD3,216,000,000USD1,432,000,000USD1,730,000,000USD627,000,000USD2,830,000,000USD
    Ebit——2,167,000,000USD4,606,000,000USD2,276,000,000USD2,696,000,000USD1,529,000,000USD3,877,000,000USD
    Ebitda——3,299,000,000USD5,913,000,000USD3,617,000,000USD4,083,000,000USD2,926,000,000USD5,273,000,000USD
    Depreciation And Amortization——1,132,000,000USD1,307,000,000USD1,341,000,000USD1,387,000,000USD1,397,000,000USD1,396,000,000USD
    Reconciled Depreciation——1,132,000,000USD1,307,000,000USD1,341,000,000USD1,387,000,000USD1,397,000,000USD1,396,000,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue36,741,000,000USD33,424,000,000USD28,190,000,000USD26,323,000,000USD25,979,000,000USD25,424,000,000USD23,362,000,000USD23,747,000,000USD
    Cost Of Revenue10,729,000,000USD12,858,000,000USD8,451,000,000USD6,406,000,000USD6,454,000,000USD6,159,000,000USD4,356,000,000USD4,101,000,000USD
    Gross Profit26,012,000,000USD20,566,000,000USD19,739,000,000USD19,917,000,000USD19,525,000,000USD19,265,000,000USD19,006,000,000USD19,646,000,000USD
    Research Development6,974,000,000USD5,964,000,000USD4,784,000,000USD4,434,000,000USD6,324,000,000USD4,207,000,000USD4,116,000,000USD3,737,000,000USD
    Selling General Administrative2,460,000,000USD6,109,000,000USD5,477,000,000USD4,573,000,000USD4,525,000,000USD4,768,000,000USD4,361,000,000USD4,658,000,000USD
    Selling And Marketing Expenses4,590,000,000USD987,000,000USD647,000,000USD841,000,000USD843,000,000USD962,000,000USD789,000,000USD674,000,000USD
    Unclassified Operating Expenses1,312,000,000USD248,000,000USD934,000,000USD503,000,000USD194,000,000USD189,000,000USD—314,000,000USD
    Total Operating Expenses15,336,000,000USD13,308,000,000USD11,842,000,000USD10,351,000,000USD11,886,000,000USD10,126,000,000USD9,332,000,000USD9,383,000,000USD
    Operating Income10,676,000,000USD7,258,000,000USD7,897,000,000USD9,566,000,000USD7,639,000,000USD9,139,000,000USD9,674,000,000USD10,263,000,000USD
    Interest Expense2,755,000,000USD3,155,000,000USD2,875,000,000USD1,406,000,000USD1,197,000,000USD1,262,000,000USD1,289,000,000USD1,392,000,000USD
    Net Interest Income-2,755,000,000USD-3,155,000,000USD-2,469,000,000USD-1,406,000,000USD-1,197,000,000USD-1,006,000,000USD-536,000,000USD-718,000,000USD
    Income Before Tax8,976,000,000USD4,609,000,000USD7,855,000,000USD7,346,000,000USD6,701,000,000USD8,133,000,000USD9,138,000,000USD9,545,000,000USD
    Income Tax Expense1,265,000,000USD519,000,000USD1,138,000,000USD794,000,000USD808,000,000USD869,000,000USD1,296,000,000USD1,151,000,000USD
    Tax Provision1,265,000,000USD519,000,000USD1,185,000,000USD794,000,000USD808,000,000USD869,000,000USD1,296,000,000USD1,151,000,000USD
    Net Income7,711,000,000USD4,090,000,000USD6,717,000,000USD6,552,000,000USD5,893,000,000USD7,264,000,000USD7,842,000,000USD8,394,000,000USD
    Net Income From Continuing Ops7,711,000,000USD4,090,000,000USD7,566,000,000USD6,552,000,000USD5,893,000,000USD7,264,000,000USD7,842,000,000USD8,394,000,000USD
    Ebit11,731,000,000USD7,764,000,000USD7,897,000,000USD8,752,000,000USD7,898,000,000USD9,395,000,000USD10,427,000,000USD10,937,000,000USD
    Ebitda16,898,000,000USD13,356,000,000USD7,897,000,000USD12,169,000,000USD11,296,000,000USD12,996,000,000USD12,633,000,000USD12,883,000,000USD
    Depreciation And Amortization5,167,000,000USD5,592,000,000USD4,071,000,000USD3,417,000,000USD3,398,000,000USD3,601,000,000USD2,206,000,000USD1,946,000,000USD
    Reconciled Depreciation5,167,000,000USD5,592,000,000USD3,602,000,000USD3,417,000,000USD3,398,000,000USD3,601,000,000USD2,206,000,000USD1,946,000,000USD
    Total Other Income Expense Net-1,700,000,000USD-2,649,000,000USD-42,000,000USD-2,220,000,000USD-938,000,000USD-1,006,000,000USD-536,000,000USD-718,000,000USD
    Non Operating Income Net Other———-814,000,000USD259,000,000USD256,000,000USD753,000,000USD674,000,000USD
    Net Income Applicable To Common Shares———6,552,000,000USD5,893,000,000USD7,264,000,000USD7,842,000,000USD8,394,000,000USD
    Interest Income—————256,000,000USD753,000,000USD674,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets95,639,000,000USD92,504,000,000USD90,586,000,000USD90,141,000,000USD87,897,000,000USD89,367,000,000USD91,839,000,000USD90,883,000,000USD
    Cash And Equivalents13,989,000,000USD12,038,000,000USD——————
    Total Current Assets34,961,000,000USD31,475,000,000USD29,057,000,000USD27,885,000,000USD26,734,000,000USD26,929,000,000USD29,030,000,000USD26,766,000,000USD
    Other Current Assets4,525,000,000USD4,113,000,000USD4,133,000,000USD3,604,000,000USD3,422,000,000USD3,258,000,000USD2,558,000,000USD3,076,000,000USD
    Other Non Current Assets12,976,000,000USD12,760,000,000USD——————
    Total Liabilities83,951,000,000USD83,314,000,000USD——————
    Total Current Liabilities25,502,000,000USD24,955,000,000USD25,489,000,000USD21,791,000,000USD20,476,000,000USD23,008,000,000USD23,099,000,000USD20,312,000,000USD
    Other Current Liabilities17,192,000,000USD16,583,000,000USD——————
    Other Non Current Liabilities2,445,000,000USD2,365,000,000USD——————
    Total Stockholder Equity11,688,000,000USD9,190,000,000USD8,658,000,000USD9,619,000,000USD7,428,000,000USD6,207,000,000USD5,877,000,000USD7,527,000,000USD
    Total Equity Including Noncontrolling Interest11,688,000,000USD9,190,000,000USD——————
    Short Long Term Debt5,445,000,000USD10,874,000,000USD4,599,000,000USD2,153,000,000USD2,444,000,000USD3,368,000,000USD3,550,000,000USD3,544,000,000USD
    Long Term Debt51,859,000,000USD51,886,000,000USD50,005,000,000USD52,434,000,000USD53,760,000,000USD54,013,000,000USD56,549,000,000USD56,854,000,000USD
    Net Receivables10,227,000,000USD9,138,000,000USD9,570,000,000USD8,490,000,000USD8,701,000,000USD8,132,000,000USD7,501,000,000USD7,317,000,000USD
    Inventory6,220,000,000USD6,186,000,000USD6,225,000,000USD6,346,000,000USD6,583,000,000USD6,729,000,000USD6,998,000,000USD7,362,000,000USD
    Property Plant Equipment Net8,547,000,000USD8,216,000,000USD8,515,000,000USD7,220,000,000USD6,855,000,000USD6,681,000,000USD6,543,000,000USD6,156,000,000USD
    Goodwill18,668,000,000USD18,674,000,000USD——————
    Intangible Assets20,487,000,000USD21,379,000,000USD22,276,000,000USD23,139,000,000USD24,614,000,000USD25,724,000,000USD27,699,000,000USD28,920,000,000USD
    Accounts Payable2,865,000,000USD2,935,000,000USD2,367,000,000USD2,838,000,000USD3,010,000,000USD2,406,000,000USD1,908,000,000USD2,147,000,000USD
    Retained Earnings-22,275,000,000USD-24,650,000,000USD-25,107,000,000USD-23,800,000,000USD-25,708,000,000USD-27,140,000,000USD-27,590,000,000USD-25,530,000,000USD
    Accumulated Other Comprehensive Income-119,000,000USD-190,000,000USD-258,000,000USD-422,000,000USD-544,000,000USD-231,000,000USD-66,000,000USD-336,000,000USD
    Total Liab——81,928,000,000USD80,522,000,000USD80,469,000,000USD83,160,000,000USD85,962,000,000USD83,356,000,000USD
    Other Current Liab——18,523,000,000USD16,800,000,000USD15,022,000,000USD17,234,000,000USD17,641,000,000USD14,621,000,000USD
    Common Stock——34,023,000,000USD33,841,000,000USD33,680,000,000USD33,578,000,000USD33,533,000,000USD33,393,000,000USD
    Capital Stock——34,023,000,000USD33,841,000,000USD33,680,000,000USD33,578,000,000USD33,533,000,000USD33,393,000,000USD
    Good Will——18,680,000,000USD18,676,000,000USD18,674,000,000USD18,645,000,000USD18,637,000,000USD18,658,000,000USD
    Cash——9,129,000,000USD9,445,000,000USD8,028,000,000USD8,810,000,000USD11,973,000,000USD9,011,000,000USD
    Cash And Short Term Investments——9,129,000,000USD9,445,000,000USD8,028,000,000USD8,810,000,000USD11,973,000,000USD9,011,000,000USD
    Net Debt——45,475,000,000USD45,142,000,000USD48,176,000,000USD48,571,000,000USD48,126,000,000USD51,387,000,000USD
    Short Term Debt——4,599,000,000USD2,153,000,000USD2,444,000,000USD3,368,000,000USD3,550,000,000USD3,544,000,000USD
    Short Long Term Debt Total——54,604,000,000USD54,587,000,000USD56,204,000,000USD57,381,000,000USD60,099,000,000USD60,398,000,000USD
    Property Plant Equipment Gross——19,033,000,000USD18,220,000,000USD17,655,000,000USD17,281,000,000USD16,931,000,000USD16,456,000,000USD
    Common Stock Shares Outstanding——543,000,000shares542,000,000shares541,000,000shares541,000,000shares542,000,000shares542,000,000shares
    Non Current Assets Total——61,529,000,000USD62,256,000,000USD61,163,000,000USD62,438,000,000USD62,809,000,000USD64,117,000,000USD
    Non Current Liabilities Total——56,439,000,000USD58,731,000,000USD59,993,000,000USD60,152,000,000USD62,863,000,000USD63,044,000,000USD
    Non Current Liabilities Other——2,378,000,000USD2,223,000,000USD2,336,000,000USD2,210,000,000USD2,349,000,000USD2,199,000,000USD
    Non Currrent Assets Other——5,254,000,000USD5,713,000,000USD6,078,000,000USD5,531,000,000USD4,575,000,000USD9,695,000,000USD
    Net Working Capital——3,568,000,000USD6,094,000,000USD6,258,000,000USD3,921,000,000USD5,931,000,000USD6,454,000,000USD
    Unclassified Non Current Assets——6,804,000,000USD7,508,000,000USD4,942,000,000USD5,857,000,000USD5,355,000,000USD688,000,000USD
    Unclassified Current Liabilities——-4,599,000,000USD-2,153,000,000USD-2,444,000,000USD-3,368,000,000USD-3,550,000,000USD-3,544,000,000USD
    Unclassified Non Current Liabilities——4,056,000,000USD4,074,000,000USD3,897,000,000USD3,929,000,000USD3,965,000,000USD3,991,000,000USD
    Unclassified Equity——-34,023,000,000USD-33,841,000,000USD-33,680,000,000USD-33,578,000,000USD-33,533,000,000USD-33,393,000,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets90,586,000,000USD91,839,000,000USD97,154,000,000USD65,121,000,000USD61,165,000,000USD62,948,000,000USD59,707,000,000USD66,416,000,000USD
    Intangible Assets22,276,000,000USD27,699,000,000USD32,641,000,000USD16,080,000,000USD15,182,000,000USD16,587,000,000USD19,413,000,000USD7,443,000,000USD
    Other Current Assets4,133,000,000USD2,558,000,000USD1,928,000,000USD1,559,000,000USD1,423,000,000USD2,079,000,000USD1,888,000,000USD1,794,000,000USD
    Total Liab81,928,000,000USD85,962,000,000USD90,922,000,000USD61,460,000,000USD54,465,000,000USD53,539,000,000USD50,034,000,000USD53,916,000,000USD
    Total Stockholder Equity8,658,000,000USD5,877,000,000USD6,232,000,000USD3,661,000,000USD6,700,000,000USD9,409,000,000USD9,673,000,000USD12,500,000,000USD
    Other Current Liab18,523,000,000USD17,641,000,000USD13,695,000,000USD11,329,000,000USD10,030,000,000USD9,313,000,000USD8,511,000,000USD7,862,000,000USD
    Common Stock34,023,000,000USD33,533,000,000USD33,070,000,000USD32,514,000,000USD32,096,000,000USD31,802,000,000USD31,531,000,000USD31,246,000,000USD
    Capital Stock34,023,000,000USD33,533,000,000USD33,070,000,000USD32,514,000,000USD32,096,000,000USD31,802,000,000USD31,531,000,000USD31,246,000,000USD
    Retained Earnings-25,107,000,000USD-27,590,000,000USD-26,549,000,000USD-28,622,000,000USD-24,600,000,000USD-21,408,000,000USD-21,330,000,000USD-17,977,000,000USD
    Good Will18,680,000,000USD18,637,000,000USD18,629,000,000USD15,529,000,000USD14,890,000,000USD14,689,000,000USD14,703,000,000USD14,699,000,000USD
    Cash9,129,000,000USD11,973,000,000USD10,944,000,000USD7,629,000,000USD7,989,000,000USD6,266,000,000USD6,037,000,000USD6,945,000,000USD
    Cash And Short Term Investments9,129,000,000USD11,973,000,000USD10,944,000,000USD9,305,000,000USD8,037,000,000USD10,647,000,000USD8,911,000,000USD29,304,000,000USD
    Total Current Assets29,057,000,000USD29,030,000,000USD30,332,000,000USD22,186,000,000USD19,385,000,000USD21,144,000,000USD18,440,000,000USD37,618,000,000USD
    Total Current Liabilities25,489,000,000USD23,099,000,000USD18,392,000,000USD15,687,000,000USD12,184,000,000USD11,653,000,000USD12,835,000,000USD13,488,000,000USD
    Net Debt45,475,000,000USD48,126,000,000USD53,669,000,000USD31,316,000,000USD25,320,000,000USD26,720,000,000USD23,866,000,000USD26,984,000,000USD
    Short Term Debt4,599,000,000USD3,550,000,000USD1,443,000,000USD1,591,000,000USD87,000,000USD91,000,000USD2,953,000,000USD4,419,000,000USD
    Short Long Term Debt4,599,000,000USD3,550,000,000USD1,443,000,000USD1,591,000,000USD87,000,000USD91,000,000USD2,953,000,000USD4,419,000,000USD
    Short Long Term Debt Total54,604,000,000USD60,099,000,000USD64,613,000,000USD38,945,000,000USD33,309,000,000USD32,986,000,000USD29,903,000,000USD33,929,000,000USD
    Long Term Debt50,005,000,000USD56,549,000,000USD63,170,000,000USD37,354,000,000USD33,222,000,000USD32,895,000,000USD26,950,000,000USD29,510,000,000USD
    Net Receivables9,570,000,000USD7,501,000,000USD7,942,000,000USD6,392,000,000USD5,839,000,000USD4,525,000,000USD4,057,000,000USD3,580,000,000USD
    Inventory6,225,000,000USD6,998,000,000USD9,518,000,000USD4,930,000,000USD4,086,000,000USD3,893,000,000USD3,584,000,000USD2,940,000,000USD
    Accounts Payable2,367,000,000USD1,908,000,000USD1,590,000,000USD1,572,000,000USD1,366,000,000USD1,421,000,000USD1,371,000,000USD1,207,000,000USD
    Property Plant Equipment Net8,515,000,000USD6,543,000,000USD5,941,000,000USD5,427,000,000USD5,184,000,000USD4,889,000,000USD4,928,000,000USD4,958,000,000USD
    Property Plant Equipment Gross19,033,000,000USD16,931,000,000USD15,749,000,000USD14,710,000,000USD13,982,000,000USD4,889,000,000USD4,928,000,000USD4,958,000,000USD
    Accumulated Other Comprehensive Income-258,000,000USD-66,000,000USD-289,000,000USD-231,000,000USD-796,000,000USD-985,000,000USD-528,000,000USD-769,000,000USD
    Common Stock Shares Outstanding542,000,000shares541,000,000shares538,000,000shares541,000,000shares573,000,000shares590,000,000shares609,000,000shares665,000,000shares
    Non Current Assets Total61,529,000,000USD62,809,000,000USD66,822,000,000USD42,935,000,000USD41,780,000,000USD41,804,000,000USD41,267,000,000USD28,798,000,000USD
    Non Current Liabilities Total56,439,000,000USD62,863,000,000USD72,530,000,000USD45,773,000,000USD42,281,000,000USD41,886,000,000USD37,199,000,000USD40,428,000,000USD
    Non Current Liabilities Other2,378,000,000USD2,349,000,000USD2,326,000,000USD2,662,000,000USD2,465,000,000USD8,991,000,000USD9,643,000,000USD10,054,000,000USD
    Non Currrent Assets Other5,254,000,000USD4,575,000,000USD4,900,000,000USD5,899,000,000USD6,524,000,000USD5,639,000,000USD2,223,000,000USD1,698,000,000USD
    Net Working Capital3,568,000,000USD5,931,000,000USD11,940,000,000USD6,499,000,000USD7,201,000,000USD9,491,000,000USD5,605,000,000USD24,130,000,000USD
    Unclassified Non Current Assets6,804,000,000USD5,355,000,000USD4,711,000,000USD-2,158,000,000USD-6,524,000,000USD-1,258,000,000USD-1,754,000,000USD-1,698,000,000USD
    Unclassified Current Liabilities-4,599,000,000USD-3,550,000,000USD221,000,000USD-396,000,000USD614,000,000USD737,000,000USD-2,953,000,000USD-4,419,000,000USD
    Unclassified Non Current Liabilities4,056,000,000USD3,965,000,000USD7,034,000,000USD-2,123,000,000USD-2,465,000,000USD-8,991,000,000USD-9,861,000,000USD-10,918,000,000USD
    Unclassified Equity-34,023,000,000USD-33,533,000,000USD-33,070,000,000USD-32,514,000,000USD-32,096,000,000USD-31,802,000,000USD-31,531,000,000USD-31,246,000,000USD
    Short Term Investments——10,944,000,000USD1,676,000,000USD48,000,000USD4,381,000,000USD2,874,000,000USD22,359,000,000USD
    Additional Paid In Capital——0USD0USD0USD0USD0USD0USD
    Treasury Stock——0USD0USD0USD0USD0USD0USD
    Unclassified Current Assets——-10,944,000,000USD—————
    Other Liab———7,880,000,000USD9,059,000,000USD8,991,000,000USD9,861,000,000USD10,918,000,000USD
    Other Assets———2,158,000,000USD6,524,000,000USD1,258,000,000USD955,000,000USD1,015,000,000USD
    Net Tangible Assets———-27,948,000,000USD-23,372,000,000USD-21,867,000,000USD-24,443,000,000USD-9,642,000,000USD
    Deferred Long Term Liab——————606,000,000USD864,000,000USD
    Long Term Investments——————799,000,000USD683,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Net Income4,194,000,000USD
    Stock Based Compensation240,000,000USD
    Deferred Income Tax-467,000,000USD
    Other Non Cash Items2,537,000,000USD
    Change To Account Receivables-680,000,000USD
    Change To Inventory-13,000,000USD
    Change To Liabilities702,000,000USD
    Change In Working Capital-313,000,000USD
    Operating Cash Flow6,191,000,000USD
    Capital Expenditures-1,225,000,000USD
    Unclassified Investing Cash Flow-60,000,000USD
    Investing Cash Flow-1,285,000,000USD
    Net Debt Issuance2,898,000,000USD
    Common Dividends Paid-2,720,000,000USD
    Other Financing Activities-224,000,000USD
    Financing Cash Flow-46,000,000USD
    Change In Cash4,860,000,000USD
    End Cash Flow13,989,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Depreciation1,116,000,000USD1,132,000,000USD1,307,000,000USD1,341,000,000USD1,387,000,000USD1,397,000,000USD1,396,000,000USD1,400,000,000USD
    Stock Based Compensation75,000,000USD125,000,000USD127,000,000USD157,000,000USD85,000,000USD134,000,000USD136,000,000USD157,000,000USD
    Deferred Income Tax-176,000,000USD———————
    Other Non Cash Items157,000,000USD898,000,000USD-1,599,000,000USD531,000,000USD-545,000,000USD868,000,000USD-1,537,000,000USD417,000,000USD
    Change To Account Receivables413,000,000USD-1,075,000,000USD222,000,000USD-515,000,000USD-1,308,000,000USD473,000,000USD-342,000,000USD-176,000,000USD
    Change To Inventory18,000,000USD119,000,000USD240,000,000USD239,000,000USD288,000,000USD323,000,000USD681,000,000USD722,000,000USD
    Change To Liabilities-463,000,000USD———————
    Change In Working Capital1,006,000,000USD-1,866,000,000USD1,663,000,000USD-759,000,000USD-1,016,000,000USD2,079,000,000USD856,000,000USD122,000,000USD
    Operating Cash Flow2,189,000,000USD———————
    Capital Expenditures-712,000,000USD-642,000,000USD-436,000,000USD-369,000,000USD-411,000,000USD-371,000,000USD-257,000,000USD-238,000,000USD
    Other Investing Activities4,000,000USD———————
    Unclassified Investing Cash Flow-8,000,000USD-53,000,000USD414,000,000USD389,000,000USD447,000,000USD402,000,000USD210,000,000USD217,000,000USD
    Investing Cash Flow-716,000,000USD———————
    Net Debt Issuance3,131,000,000USD———————
    Common Dividends Paid-1,358,000,000USD———————
    Other Financing Activities-104,000,000USD———————
    Unclassified Financing Cash Flow-233,000,000USD—-81,000,000USD-301,000,000USD-301,000,000USD4,010,000,000USD—-1,400,000,000USD
    Financing Cash Flow1,436,000,000USD———————
    Change In Cash2,909,000,000USD-316,000,000USD1,417,000,000USD-782,000,000USD-3,163,000,000USD2,962,000,000USD-290,000,000USD-407,000,000USD
    End Cash Flow12,038,000,000USD———————
    Net Income—1,333,000,000USD3,216,000,000USD1,432,000,000USD1,730,000,000USD627,000,000USD2,830,000,000USD746,000,000USD
    Total Cash From Operating Activities—1,603,000,000USD4,684,000,000USD2,280,000,000USD1,391,000,000USD4,771,000,000USD3,571,000,000USD2,459,000,000USD
    Free Cash Flow—961,000,000USD4,248,000,000USD1,911,000,000USD980,000,000USD4,400,000,000USD3,314,000,000USD2,221,000,000USD
    Total Cashflows From Investing Activities—-693,000,000USD-414,000,000USD-389,000,000USD-447,000,000USD-402,000,000USD-210,000,000USD-217,000,000USD
    Net Borrowings—0USD-1,500,000,000USD-1,000,000,000USD-2,500,000,000USD0USD-2,200,000,000USD—
    Total Cash From Financing Activities—-1,226,000,000USD-2,853,000,000USD-2,673,000,000USD-4,107,000,000USD-1,407,000,000USD-3,651,000,000USD-2,649,000,000USD
    Dividends Paid—-1,283,000,000USD-1,282,000,000USD-1,280,000,000USD-1,279,000,000USD-1,205,000,000USD-1,210,000,000USD-1,209,000,000USD
    Begin Period Cash Flow—9,445,000,000USD8,028,000,000USD8,810,000,000USD11,973,000,000USD9,011,000,000USD9,301,000,000USD9,708,000,000USD
    End Period Cash Flow—9,129,000,000USD9,445,000,000USD8,028,000,000USD8,810,000,000USD11,973,000,000USD9,011,000,000USD9,301,000,000USD
    Other Cashflows From Investing Activities—2,000,000USD22,000,000USD-20,000,000USD-36,000,000USD-31,000,000USD47,000,000USD21,000,000USD
    Other Cashflows From Financing Activities—57,000,000USD10,000,000USD-92,000,000USD-27,000,000USD-4,012,000,000USD-241,000,000USD-40,000,000USD
    Unclassified Operating Cash Flow—-19,000,000USD—-422,000,000USD-250,000,000USD-334,000,000USD-110,000,000USD-383,000,000USD
    Investments——-414,000,000USD-389,000,000USD-447,000,000USD-402,000,000USD-210,000,000USD-217,000,000USD
    Sale Purchase Of Stock—————-200,000,000USD——
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income7,711,000,000USD4,090,000,000USD6,717,000,000USD6,552,000,000USD5,893,000,000USD7,264,000,000USD7,842,000,000USD8,394,000,000USD
    Depreciation5,167,000,000USD5,592,000,000USD4,071,000,000USD3,417,000,000USD3,398,000,000USD3,601,000,000USD2,206,000,000USD1,946,000,000USD
    Stock Based Compensation494,000,000USD530,000,000USD431,000,000USD401,000,000USD341,000,000USD330,000,000USD308,000,000USD311,000,000USD
    Other Non Cash Items-715,000,000USD141,000,000USD-991,000,000USD1,282,000,000USD1,276,000,000USD-195,000,000USD-186,000,000USD386,000,000USD
    Change To Account Receivables-2,676,000,000USD441,000,000USD-1,015,000,000USD-746,000,000USD-429,000,000USD-427,000,000USD-504,000,000USD-378,000,000USD
    Change To Inventory886,000,000USD2,532,000,000USD491,000,000USD-742,000,000USD-165,000,000USD-215,000,000USD-66,000,000USD-3,000,000USD
    Change In Working Capital-1,978,000,000USD2,365,000,000USD-484,000,000USD-733,000,000USD-1,194,000,000USD-216,000,000USD-731,000,000USD622,000,000USD
    Total Cash From Operating Activities9,958,000,000USD11,490,000,000USD8,471,000,000USD9,721,000,000USD9,261,000,000USD10,497,000,000USD9,150,000,000USD11,296,000,000USD
    Capital Expenditures-1,858,000,000USD-1,096,000,000USD-1,112,000,000USD-936,000,000USD-880,000,000USD-608,000,000USD-618,000,000USD-738,000,000USD
    Free Cash Flow8,100,000,000USD10,394,000,000USD7,359,000,000USD8,785,000,000USD8,381,000,000USD9,889,000,000USD8,532,000,000USD10,558,000,000USD
    Investments0USD-1,046,000,000USD-2,588,000,000USD-6,044,000,000USD733,000,000USD-4,718,000,000USD19,996,000,000USD15,027,000,000USD
    Total Cashflows From Investing Activities-1,943,000,000USD-1,046,000,000USD-26,204,000,000USD-6,044,000,000USD733,000,000USD-5,401,000,000USD5,709,000,000USD14,339,000,000USD
    Net Borrowings-5,000,000,000USD-3,600,000,000USD26,323,000,000USD6,622,000,000USD795,000,000USD2,464,000,000USD-4,514,000,000USD-1,121,000,000USD
    Total Cash From Financing Activities-10,859,000,000USD-9,415,000,000USD21,048,000,000USD-4,037,000,000USD-8,271,000,000USD-4,867,000,000USD-15,767,000,000USD-22,490,000,000USD
    Dividends Paid-5,124,000,000USD-4,832,000,000USD-4,556,000,000USD-4,196,000,000USD-4,013,000,000USD-3,755,000,000USD-3,509,000,000USD-3,507,000,000USD
    Sale Purchase Of Stock0USD-200,000,000USD0USD-6,360,000,000USD-4,975,000,000USD-3,486,000,000USD-7,702,000,000USD-17,794,000,000USD
    Change In Cash-2,844,000,000USD1,029,000,000USD3,315,000,000USD-360,000,000USD1,723,000,000USD229,000,000USD-908,000,000USD3,145,000,000USD
    Begin Period Cash Flow11,973,000,000USD10,944,000,000USD7,629,000,000USD7,989,000,000USD6,266,000,000USD6,037,000,000USD6,945,000,000USD3,800,000,000USD
    End Period Cash Flow9,129,000,000USD11,973,000,000USD10,944,000,000USD7,629,000,000USD7,989,000,000USD6,266,000,000USD6,037,000,000USD6,945,000,000USD
    Other Cashflows From Investing Activities-32,000,000USD50,000,000USD225,000,000USD-3,721,000,000USD1,613,000,000USD-75,000,000USD-13,669,000,000USD-145,000,000USD
    Other Cashflows From Financing Activities-52,000,000USD-124,000,000USD-72,000,000USD6,519,000,000USD-78,000,000USD-90,000,000USD-42,000,000USD-68,000,000USD
    Unclassified Operating Cash Flow-721,000,000USD-1,228,000,000USD-1,273,000,000USD-1,198,000,000USD-453,000,000USD-287,000,000USD-289,000,000USD-363,000,000USD
    Unclassified Investing Cash Flow-53,000,000USD1,046,000,000USD-22,729,000,000USD4,657,000,000USD-733,000,000USD——195,000,000USD
    Unclassified Financing Cash Flow-683,000,000USD-659,000,000USD-647,000,000USD-6,622,000,000USD————
    Change To Liabilities———268,000,000USD-567,000,000USD779,000,000USD-25,000,000USD710,000,000USD
    Cash And Cash Equivalents Changes———-360,000,000USD1,723,000,000USD229,000,000USD-908,000,000USD3,145,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    BLINCYTO volume growth

    Period endPeriodValueUnitSource
    2026-06-30quarter16percentDisclosure

    ENBREL net selling price change

    Period endPeriodValueUnitSource
    2026-06-30quarter-22percentDisclosure

    KRYSTEXXA net selling price change

    Period endPeriodValueUnitSource
    2026-06-30quarter23percentDisclosure

    Nplate volume growth

    Period endPeriodValueUnitSource
    2026-06-30quarter13percentDisclosure

    Otezla net selling price change

    Period endPeriodValueUnitSource
    2026-06-30quarter-9percentDisclosure

    Otezla volume growth

    Period endPeriodValueUnitSource
    2026-06-30quarter-6percentDisclosure

    Prolia net selling price change

    Period endPeriodValueUnitSource
    2026-06-30quarter-12percentDisclosure

    Prolia volume growth

    Period endPeriodValueUnitSource
    2026-06-30quarter-20percentDisclosure

    ROW product sales volume growth

    Period endPeriodValueUnitSource
    2026-06-30quarter8percentDisclosure

    TEPEZZA net selling price change

    Period endPeriodValueUnitSource
    2026-06-30quarter6percentDisclosure

    TEPEZZA volume growth

    Period endPeriodValueUnitSource
    2026-06-30quarter6percentDisclosure

    Total product sales volume growth

    Period endPeriodValueUnitSource
    2026-06-30year_to_date9percentDisclosure

    U.S. product sales volume growth

    Period endPeriodValueUnitSource
    2026-06-30quarter9percentDisclosure

    XGEVA net selling price change

    Period endPeriodValueUnitSource
    2026-06-30quarter-8percentDisclosure

    XGEVA volume growth

    Period endPeriodValueUnitSource
    2026-06-30quarter-22percentDisclosure

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductProduct9,537,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProduct And Service Other517,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductProduct8,218,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductProduct And Service Other400,000,000USDDisclosure
    Q4 2025Quarterly · 2025-12-31ProductProduct9,367,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductProduct And Service Other499,000,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyInternational10,332,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyUnited States26,419,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductProduct35,148,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductProduct And Service Other1,603,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductProduct9,137,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductProduct And Service Other420,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductProduct8,771,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductProduct And Service Other408,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductProduct8,716,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductProduct And Service Other370,000,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyInternational9,561,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31GeographyUnited States23,863,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductProduct32,026,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductProduct And Service Other1,398,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductProduct8,151,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductProduct And Service Other352,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30ProductProduct8,041,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30ProductProduct And Service Other347,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31GeographyInternational8,384,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31GeographyUnited States19,806,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31ProductProduct26,910,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31ProductProduct And Service Other1,280,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31GeographyInternational7,728,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31GeographyUnited States18,595,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31ProductProduct24,801,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31ProductProduct And Service Other1,522,000,000USDDisclosure
    FY 2021Yearly · 2021-12-31GeographyInternational7,785,000,000USD0000318154-24-000011
    FY 2021Yearly · 2021-12-31GeographyUnited States18,194,000,000USD0000318154-24-000011
    FY 2021Yearly · 2021-12-31ProductProduct24,297,000,000USD0000318154-24-000011
    FY 2021Yearly · 2021-12-31ProductProduct And Service Other1,682,000,000USD0000318154-24-000011
    FY 2020Yearly · 2020-12-31GeographyInternational6,928,000,000USD0000318154-23-000017
    FY 2020Yearly · 2020-12-31GeographyUnited States18,496,000,000USD0000318154-23-000017
    FY 2020Yearly · 2020-12-31ProductAranesp1,568,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductEnbrel4,996,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductKyprolis1,065,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductNeulasta2,293,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductOtezla2,195,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductOther Products6,574,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductProduct And Service Other1,184,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductProlia2,763,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductRepathaevolocumab887,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductRoyalty217,000,000USD0000318154-21-000010
    FY 2020Yearly · 2020-12-31ProductXgeva1,899,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31GeographyInternational6,138,000,000USD0000318154-22-000010
    FY 2019Yearly · 2019-12-31GeographyUnited States17,224,000,000USD0000318154-22-000010
    FY 2019Yearly · 2019-12-31ProductAranesp1,729,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductEnbrel5,226,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductKyprolis1,044,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductNeulasta3,221,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductOtezla178,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductOther Products5,538,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductProduct And Service Other1,158,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductProlia2,672,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductRepathaevolocumab661,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductRoyalty79,000,000USD0000318154-21-000010
    FY 2019Yearly · 2019-12-31ProductXgeva1,935,000,000USD0000318154-21-000010
    FY 2018Yearly · 2018-12-31GeographyInternational5,389,000,000USD0000318154-21-000010
    FY 2018Yearly · 2018-12-31GeographyUnited States18,358,000,000USD0000318154-21-000010
    FY 2018Yearly · 2018-12-31ProductAranesp — Royalty91,000,000USD0000318154-19-000008
    FY 2018Yearly · 2018-12-31ProductAranesp — Xgeva1,786,000,000USD0000318154-19-000008
    FY 2018Yearly · 2018-12-31ProductEnbrel5,014,000,000USD0000318154-19-000008
    FY 2018Yearly · 2018-12-31ProductEpogen1,010,000,000USD0000318154-19-000008
    FY 2018Yearly · 2018-12-31ProductNeulasta4,475,000,000USD0000318154-19-000008
    FY 2018Yearly · 2018-12-31ProductOther Products7,306,000,000USD0000318154-19-000008
    FY 2018Yearly · 2018-12-31ProductProlia2,291,000,000USD0000318154-19-000008
    FY 2018Yearly · 2018-12-31ProductSensipar Mimpara1,774,000,000USD0000318154-19-000008

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.